Abstract
Members of epidermal growth factor receptor (EGFR) or ErbB receptor family play a critical role in a wide range of human cancers. In the past decade, there has been a remarkable progress in developing ErbB targeted therapeutics. However, a substantial portion of patients has non-responsive disease or subsequently shows evidence of tumour relapse following initial success with anti-ErbB agents. Improved insights into the biology of ErbB receptor family have led to more effective second- and third-generation anti-ErbB therapies. In this review, we have summarised salient features of the ErbB receptor physiology and highlighted key mechanisms involved in abnormal ErbB signalling in tumorigenesis. The rationale of anti-ErbB receptor therapies are outlined along with key mechanisms proposed for resistance to treatment as well as the current concept of combined anti-ErbB therapies. In conclusion, improved understanding of the molecular pathways that confer resistance to anti-ErbB therapeutics will be essential in minimising tumour resistance to ErbB targeted treatments.
Keywords: EGFR, ErbB, receptor tyrosine kinase, monoclonal antibodies, small molecule inhibitors, cancers, tumorigenesis, tumour resistance, dimerization, gene amplifications
Current Pharmaceutical Design
Title:Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Volume: 18 Issue: 19
Author(s): Rachana Patel and Hing Y. Leung
Affiliation:
Keywords: EGFR, ErbB, receptor tyrosine kinase, monoclonal antibodies, small molecule inhibitors, cancers, tumorigenesis, tumour resistance, dimerization, gene amplifications
Abstract: Members of epidermal growth factor receptor (EGFR) or ErbB receptor family play a critical role in a wide range of human cancers. In the past decade, there has been a remarkable progress in developing ErbB targeted therapeutics. However, a substantial portion of patients has non-responsive disease or subsequently shows evidence of tumour relapse following initial success with anti-ErbB agents. Improved insights into the biology of ErbB receptor family have led to more effective second- and third-generation anti-ErbB therapies. In this review, we have summarised salient features of the ErbB receptor physiology and highlighted key mechanisms involved in abnormal ErbB signalling in tumorigenesis. The rationale of anti-ErbB receptor therapies are outlined along with key mechanisms proposed for resistance to treatment as well as the current concept of combined anti-ErbB therapies. In conclusion, improved understanding of the molecular pathways that confer resistance to anti-ErbB therapeutics will be essential in minimising tumour resistance to ErbB targeted treatments.
Export Options
About this article
Cite this article as:
Patel Rachana and Y. Leung Hing, Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626148
DOI https://dx.doi.org/10.2174/138161212800626148 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipoproteins, Stroke and Statins
Current Vascular Pharmacology An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders Metabolic Features of Alcoholic Liver Disease
Reviews on Recent Clinical Trials Editorial [Hot Topic: Vascular Complications of Diabetes (Executive Editor: Olga I. Stenina)]
Current Pharmaceutical Design Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design Expression of microRNAs (133b and 138) and Correlation with Echocardiographic Parameters in Patients with Alcoholic Cardiomyopathy
MicroRNA Cardiac Mitochondrial Alterations Observed in Hyperglycaemic Rats - What Can We Learn From Cell Biology?
Current Diabetes Reviews Interatrial Block in the Modern Era
Current Cardiology Reviews SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons
Current Cardiology Reviews Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) HIV-1-Infected Long-Term Non-Progressors have Milder Mitochondrial Impairment and Lower Mitochondrially-Driven Apoptosis in Peripheral Blood Mononuclear Cells than Typical Progressors
Current HIV Research Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Pharmacokinetic Considerations of Perinatal Antiretroviral Therapy
Current Drug Metabolism Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
Current Nutraceuticals Targeting Prenylated RAS Modifying Enzymes in Cancer Cells
Current Signal Transduction Therapy Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology